Horst Helbig
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Horst Helbig has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
David Maerker
Department of Ophthalmology, University Hospital of Regensburg, Regensburg, Germany
2 shared publicationsMaria-Andreea Gamulescu
Department of Ophthalmology, University Hospital of Regensburg, Regensburg, Germany
2 shared publicationsPhilipp Prahs
Department of Ophthalmology, University Hospital of Regensburg, Regensburg, Germany
2 shared publications- Teresa Barth
Klinik und Poliklinik für Augenheilkunde, Universitätsklinikum Regensburg, Regensburg, Deutschland
2 shared publications - Ulrich Kellner
Rare Retinal Disease Center, AugenZentrum Siegburg, MVZ Augenärztliches Diagnostik- und Therapiezentrum Siegburg GmbH, Europaplatz 3, 53721 Siegburg, Germany
2 shared publications Viola Radeck
Department of Ophthalmology, University Hospital of Regensburg, Regensburg, Germany
2 shared publications
Latest Publications
- 16 January 2025
- Published by Georg Thieme Verlag KG in Klinische Monatsblätter für Augenheilkunde
- Vol. 242 (03) , 196-198
Die neue Generation der Anti-VEGF-Wirkstoffe: Sind sie wirklich besser?
Bevor die im Titel gestellt Frage detailliert beantwortet werden kann, muss zunächst definiert werden, aus welcher Perspektive sie betrachtet werden soll und was „besser“ bedeutet. Article published online: 16 January 2025 © 2025. Thieme. All rights reserved. Georg Thieme Verlag KG Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany
- 16 January 2025
- Published by Georg Thieme Verlag KG in Klinische Monatsblätter für Augenheilkunde
- Vol. 242 (03) , 196-198
Die neue Generation der Anti-VEGF-Wirkstoffe: Sind sie wirklich besser?
Bevor die im Titel gestellt Frage detailliert beantwortet werden kann, muss zunächst definiert werden, aus welcher Perspektive sie betrachtet werden soll und was „besser“ bedeutet. Article published online: 16 January 2025 © 2025. Thieme. All rights reserved. Georg Thieme Verlag KG Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany
- Open Access
- 25 October 2022
- Published by S. Karger AG in Ophthalmologica
- Vol. 246 (2) , 99-106
Characteristics of Bilateral Retinal Detachment
Introduction: Rhegmatogenous retinal detachment (RD) is still a sight-threatening and potentially blinding disease, especially if both eyes are affected. The purpose of this study is analysing the specific characteristics of bilateral rhegmatogenous RD. Methods: The files of all 5,791 consecutive eyes undergoing vitreoretinal surgery for uncomplicated RD in a single tertiary retinal centre between January 2005 and June 2021 were retrospectively reviewed. Results: A total of 300 patients (600 eyes) had bilateral retinal detachment. Interval between initial and subsequent RD surgery was 2.6 ± 2.8 (mean ± SD, median 1.5) years. Symptoms were reported by the patients for 20 ± 75 (median 5) days before presentation in the initial eye and 12 ± 32 (median 4) days in the subsequent eye. 220 patients were male (73%), and mean age at initial RD was 55 years. 183 (61%) of the initial RD eyes were phakic. In the initial eye, more patients had a detached macula, worse visual acuity, and more quadrants involved. Primary anatomic success rate was higher in the subsequent eye (90%) compared to the initial eye (83%). There was no difference in the reattachment rate of fellow eyes with primary failure in the first eye (91%) compared to those with primary success in the first eye (90%). There was a high symmetry between the eyes in terms of type of retinal break, number of breaks, and presumed localization of the causative retinal break. Conclusion: Patients with bilateral RD were more commonly male and younger than the group of all RD patients. The proportion of pseudophakia was not different. The majority of fellow eye RD occurred within 2 years after the RD in the first eye. Second eye RD was less advanced and had a better anatomical repair rate. Despite their experience in the first eye and despite typical symptoms, patients presented only after a mean of 12 days with RD in the second eye. RD in the initial and the subsequent eye showed a high symmetry. The anatomic result in the first eye is not a predictor for the anatomic result in the subsequent eye.
- 25 October 2022
- Published by S. Karger AG in Ophthalmologica
- Vol. 246 (2) , 99-106
Open AccessCharacteristics of Bilateral Retinal Detachment
Introduction: Rhegmatogenous retinal detachment (RD) is still a sight-threatening and potentially blinding disease, especially if both eyes are affected. The purpose of this study is analysing the specific characteristics of bilateral rhegmatogenous RD. Methods: The files of all 5,791 consecutive eyes undergoing vitreoretinal surgery for uncomplicated RD in a single tertiary retinal centre between January 2005 and June 2021 were retrospectively reviewed. Results: A total of 300 patients (600 eyes) had bilateral retinal detachment. Interval between initial and subsequent RD surgery was 2.6 ± 2.8 (mean ± SD, median 1.5) years. Symptoms were reported by the patients for 20 ± 75 (median 5) days before presentation in the initial eye and 12 ± 32 (median 4) days in the subsequent eye. 220 patients were male (73%), and mean age at initial RD was 55 years. 183 (61%) of the initial RD eyes were phakic. In the initial eye, more patients had a detached macula, worse visual acuity, and more quadrants involved. Primary anatomic success rate was higher in the subsequent eye (90%) compared to the initial eye (83%). There was no difference in the reattachment rate of fellow eyes with primary failure in the first eye (91%) compared to those with primary success in the first eye (90%). There was a high symmetry between the eyes in terms of type of retinal break, number of breaks, and presumed localization of the causative retinal break. Conclusion: Patients with bilateral RD were more commonly male and younger than the group of all RD patients. The proportion of pseudophakia was not different. The majority of fellow eye RD occurred within 2 years after the RD in the first eye. Second eye RD was less advanced and had a better anatomical repair rate. Despite their experience in the first eye and despite typical symptoms, patients presented only after a mean of 12 days with RD in the second eye. RD in the initial and the subsequent eye showed a high symmetry. The anatomic result in the first eye is not a predictor for the anatomic result in the subsequent eye.
- 29 September 2021
- Published by Georg Thieme Verlag KG in Klinische Monatsblätter für Augenheilkunde
- Vol. 238 (12) , 1299-1304
Thermal Laser Monotherapy for Extrafoveal Polypoidal Choroidal Vasculopathy
Introduction Polypoidal choroidal vasculopathy (PCV) is a vascular disease of the choroid. Diagnosis is mainly based on polypoidal aneurysm-like lesions seen in indocyanine green (ICG) angiography. Various therapeutic options have been proposed. Methods Outcomes of 10 cases with extrafoveal PCV and consecutive macular edema treated with thermal laser are reported. Diagnosis of PCV was confirmed by ICG angiography. Results Upon successful occlusion of the polyps in 10 eyes after thermal laser treatment demonstrated in ICG angiography, a regression of central foveal edema was seen in optical coherence tomography and color fundus photography. Visual acuity improved from logMAR 0.8 to logMAR 0.3. Follow-up ranged from 4 months to 15 years, with a median of 1 year. Two eyes had a recurrence of exudative maculopathy 5 and 7 years after laser treatment, respectively. Conclusion A careful differentiation between various subforms of exudative maculopathy using fluorescein and ICG angiography can identify certain selected patients with extrafoveal PCV, for whom thermal laser monotherapy can be a therapeutic option.
- 29 September 2021
- Published by Georg Thieme Verlag KG in Klinische Monatsblätter für Augenheilkunde
- Vol. 238 (12) , 1299-1304
Thermal Laser Monotherapy for Extrafoveal Polypoidal Choroidal Vasculopathy
Introduction Polypoidal choroidal vasculopathy (PCV) is a vascular disease of the choroid. Diagnosis is mainly based on polypoidal aneurysm-like lesions seen in indocyanine green (ICG) angiography. Various therapeutic options have been proposed. Methods Outcomes of 10 cases with extrafoveal PCV and consecutive macular edema treated with thermal laser are reported. Diagnosis of PCV was confirmed by ICG angiography. Results Upon successful occlusion of the polyps in 10 eyes after thermal laser treatment demonstrated in ICG angiography, a regression of central foveal edema was seen in optical coherence tomography and color fundus photography. Visual acuity improved from logMAR 0.8 to logMAR 0.3. Follow-up ranged from 4 months to 15 years, with a median of 1 year. Two eyes had a recurrence of exudative maculopathy 5 and 7 years after laser treatment, respectively. Conclusion A careful differentiation between various subforms of exudative maculopathy using fluorescein and ICG angiography can identify certain selected patients with extrafoveal PCV, for whom thermal laser monotherapy can be a therapeutic option.
- Open Access
- 5 February 2021
- Published by Springer Nature in Graefe's Archive for Clinical and Experimental Ophthalmology
- Vol. 259 (8) , 2167-2173
The learning curve of retinal detachment surgery
Purpose: To investigate the learning curve of vitreoretinal (VR) surgeons beginning training in retinal detachment (RD) surgery. Methods: The files of all consecutive patients undergoing VR surgery for uncomplicated RD between Jan 2005 und Mar 2020 were retrospectively reviewed. Successful outcome was defined as no retinal redetachment within 3 months after surgery. Results: Ten surgeons started their VR career during this period. Together, these 10 surgeons performed 3786 RD operations (mean 379; median 251; range 71–1053). Primary success rate after one operation was 90% (3420 of 3786). When starting to operate retinal detachments, VR surgeons had a primary success rate of about 80%. Redetachment rates steadily decreased and stabilized at just under 10% after about 200 operations. Beginners needed more than twice the time for the procedure compared to experienced surgeons. The individual learning curves varied widely. In our series, female surgeons seem to have a faster learning curve. Conclusion: RD surgery performed by VR surgeons in training had acceptable results. With increasing experience, success rates continuously improve reaching stable levels after approximately 200 operations. The training of VR surgeons requires considerable resources.
- 5 February 2021
- Published by Springer Nature in Graefe's Archive for Clinical and Experimental Ophthalmology
- Vol. 259 (8) , 2167-2173
Open AccessThe learning curve of retinal detachment surgery
Purpose: To investigate the learning curve of vitreoretinal (VR) surgeons beginning training in retinal detachment (RD) surgery. Methods: The files of all consecutive patients undergoing VR surgery for uncomplicated RD between Jan 2005 und Mar 2020 were retrospectively reviewed. Successful outcome was defined as no retinal redetachment within 3 months after surgery. Results: Ten surgeons started their VR career during this period. Together, these 10 surgeons performed 3786 RD operations (mean 379; median 251; range 71–1053). Primary success rate after one operation was 90% (3420 of 3786). When starting to operate retinal detachments, VR surgeons had a primary success rate of about 80%. Redetachment rates steadily decreased and stabilized at just under 10% after about 200 operations. Beginners needed more than twice the time for the procedure compared to experienced surgeons. The individual learning curves varied widely. In our series, female surgeons seem to have a faster learning curve. Conclusion: RD surgery performed by VR surgeons in training had acceptable results. With increasing experience, success rates continuously improve reaching stable levels after approximately 200 operations. The training of VR surgeons requires considerable resources.
- 28 May 2020
- Published by Springer Nature in Der Ophthalmologe
- Vol. 117 (6) , 579-590
Pseudophakes zystoides Makulaödem
Pseudophakic cystoid macular edema (PCME) is still one of the most frequent causes of loss of vision after cataract surgery. Clinical PCME occurs after initial improvement of vision 2-10 weeks after surgery in 1-2% with secondary vision loss and biomicroscopically visible macular cysts. Alterations, which are often not associated with functional limitations, can frequently be seen with angiography and optical coherence tomography (OCT). Inflammation mediators are released due to the surgical trauma in the anterior segment of the eye and diffuse to the capillaries of the macula where they lead to exudation of fluid into the retinal tissue and swelling of the macula. Risk factors for PCME are complicated cataract surgery, diabetes, uveitis, epiretinal gliosis and a status after retinal vein occlusion. In eyes at risk, perioperative prophylaxis with topical nonsteroidal anti-inflammatory drugs should be prescribed. The natural course of PCME is often benign with spontaneous recovery over several months; however, to avoid irreversible loss of vision treatment should be initiated.
- 28 May 2020
- Published by Springer Nature in Der Ophthalmologe
- Vol. 117 (6) , 579-590
Pseudophakes zystoides Makulaödem
Pseudophakic cystoid macular edema (PCME) is still one of the most frequent causes of loss of vision after cataract surgery. Clinical PCME occurs after initial improvement of vision 2-10 weeks after surgery in 1-2% with secondary vision loss and biomicroscopically visible macular cysts. Alterations, which are often not associated with functional limitations, can frequently be seen with angiography and optical coherence tomography (OCT). Inflammation mediators are released due to the surgical trauma in the anterior segment of the eye and diffuse to the capillaries of the macula where they lead to exudation of fluid into the retinal tissue and swelling of the macula. Risk factors for PCME are complicated cataract surgery, diabetes, uveitis, epiretinal gliosis and a status after retinal vein occlusion. In eyes at risk, perioperative prophylaxis with topical nonsteroidal anti-inflammatory drugs should be prescribed. The natural course of PCME is often benign with spontaneous recovery over several months; however, to avoid irreversible loss of vision treatment should be initiated.
- 11 September 2019
- Published by Georg Thieme Verlag KG in Klinische Monatsblätter für Augenheilkunde
- Vol. 236 (09) , 1066-1067
Therapeutische Ansätze für die trockene altersabhängige Makuladegeneration
Die altersabhängige Makuladegeneration (AMD) ist die mit Abstand häufigste Ursache für eine Sehbehinderung in den Industrienationen. Unterschieden wird die exsudative und die nicht exsudative, „trockene“ Form der AMD. Letztere ist dabei wesentlich häufiger. Für die exsudative AMD haben wir mit den Anti-VEGF-Medikamenten eine wirksame Therapie zur Verfügung. An dieser Stelle soll aber noch einmal daran erinnert werden, dass die Anti-VEGF-Therapie nur die Exsudation der CNV therapiert, also nur eine Komplikation eines primär degenerativen Prozesses. Eine wirklich ursächliche Behandlung für diese Degeneration gibt es nicht. Für die trockene AMD gibt es keine Therapie. Wegen der enormen Bedeutung der Erkrankung für den individuellen Patienten, das Gesundheitswesen und die Volkswirtschaft besteht ein ausgesprochen hoher Bedarf, hier Abhilfe zu schaffen und die Sehbehinderung von Millionen Menschen zu verhindern oder zumindest aufzuhalten. Dieses Schwerpunktheft der „Klinischen Monatsblätter“ soll Ihnen eine Übersicht über den aktuellen Wissensstand vermitteln.
- 11 September 2019
- Published by Georg Thieme Verlag KG in Klinische Monatsblätter für Augenheilkunde
- Vol. 236 (09) , 1066-1067
Therapeutische Ansätze für die trockene altersabhängige Makuladegeneration
Die altersabhängige Makuladegeneration (AMD) ist die mit Abstand häufigste Ursache für eine Sehbehinderung in den Industrienationen. Unterschieden wird die exsudative und die nicht exsudative, „trockene“ Form der AMD. Letztere ist dabei wesentlich häufiger. Für die exsudative AMD haben wir mit den Anti-VEGF-Medikamenten eine wirksame Therapie zur Verfügung. An dieser Stelle soll aber noch einmal daran erinnert werden, dass die Anti-VEGF-Therapie nur die Exsudation der CNV therapiert, also nur eine Komplikation eines primär degenerativen Prozesses. Eine wirklich ursächliche Behandlung für diese Degeneration gibt es nicht. Für die trockene AMD gibt es keine Therapie. Wegen der enormen Bedeutung der Erkrankung für den individuellen Patienten, das Gesundheitswesen und die Volkswirtschaft besteht ein ausgesprochen hoher Bedarf, hier Abhilfe zu schaffen und die Sehbehinderung von Millionen Menschen zu verhindern oder zumindest aufzuhalten. Dieses Schwerpunktheft der „Klinischen Monatsblätter“ soll Ihnen eine Übersicht über den aktuellen Wissensstand vermitteln.
- 24 August 2017
- Published by Springer Nature
- p. 153-161
Retinal Pigment Epithelial Detachment in Systemic Disease
- 24 August 2017
- Published by Springer Nature
- p. 153-161
Retinal Pigment Epithelial Detachment in Systemic Disease
- Open Access
- 11 August 2016
- Published by Springer Nature in Der Ophthalmologe
- Vol. 113 (9) , 732-734
Epidemiologie der Volkskrankheiten in der Augenheilkunde
- 11 August 2016
- Published by Springer Nature in Der Ophthalmologe
- Vol. 113 (9) , 732-734
Open AccessEpidemiologie der Volkskrankheiten in der Augenheilkunde
- 2 July 2015
- Published by Springer Nature in Der Ophthalmologe
- Vol. 112 (11) , 888-889
Individualisierte Therapie bei AMD? Gentests nicht sinnvoll
- 2 July 2015
- Published by Springer Nature in Der Ophthalmologe
- Vol. 112 (11) , 888-889
Individualisierte Therapie bei AMD? Gentests nicht sinnvoll
- 20 August 2014
- Published by Springer Nature in Der Ophthalmologe
- Vol. 112 (2) , 166-170
Konjunktivale Amyloidose
This article reports a case of primary localized conjunctival λ light-chain (AL) amyloidosis. Case report. A 73-year-old woman presented with a 1-year history of a painless growth in the conjunctiva of the left eye. A yellow-salmon pink diffuse mass of tissue was identified in the inferomedial bulbar conjunctiva and inferior fornix. An incisional biopsy was performed. The histopathological and immunohistochemical examinations revealed interstitial and vascular amyloid deposits of λ light chains. The diagnosis was amyloidosis of the conjunctiva. The systemic evaluation revealed normal findings and systemic amyloidosis was excluded. Nevertheless, due to an unexplained cardiac insufficiency and after consultation with the treating hematologist a treatment with three cycles of systemic chemotherapy with melphalan and prednisolone was initiated but 6 months later the conjunctival mass in the inferior fornix showed persistence and complete excision was performed. At 16, 24 and 44 months of follow-up no evidence of recurrence was seen on clinical examination. The magnetic resonance imaging (MRI) at 16 and 24 months of follow-up showed no associated cranial or orbital infiltration. Conjunctival AL amyloidosis is a rare clinical entity. Because of the heterogeneity of amyloidosis in clinical presentation, pattern of amyloid-related organ toxicity, association with lymphoproliferative diseases and rate of disease progression, identification of amyloid deposits is essential and systemic involvement has to be excluded.
- 20 August 2014
- Published by Springer Nature in Der Ophthalmologe
- Vol. 112 (2) , 166-170
Konjunktivale Amyloidose
This article reports a case of primary localized conjunctival λ light-chain (AL) amyloidosis. Case report. A 73-year-old woman presented with a 1-year history of a painless growth in the conjunctiva of the left eye. A yellow-salmon pink diffuse mass of tissue was identified in the inferomedial bulbar conjunctiva and inferior fornix. An incisional biopsy was performed. The histopathological and immunohistochemical examinations revealed interstitial and vascular amyloid deposits of λ light chains. The diagnosis was amyloidosis of the conjunctiva. The systemic evaluation revealed normal findings and systemic amyloidosis was excluded. Nevertheless, due to an unexplained cardiac insufficiency and after consultation with the treating hematologist a treatment with three cycles of systemic chemotherapy with melphalan and prednisolone was initiated but 6 months later the conjunctival mass in the inferior fornix showed persistence and complete excision was performed. At 16, 24 and 44 months of follow-up no evidence of recurrence was seen on clinical examination. The magnetic resonance imaging (MRI) at 16 and 24 months of follow-up showed no associated cranial or orbital infiltration. Conjunctival AL amyloidosis is a rare clinical entity. Because of the heterogeneity of amyloidosis in clinical presentation, pattern of amyloid-related organ toxicity, association with lymphoproliferative diseases and rate of disease progression, identification of amyloid deposits is essential and systemic involvement has to be excluded.